🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The US and EU failed to negotiate for a peoples' vaccine. C-TAP would be the right platform for funders, companies, and researchers, especially in developing countries, to create a real peoples' vaccine!

C-TAP co-sponsors and interested states, working together, could create powerful incentives for private sector companies to jump into the pool!

If a European "C-TAP" is good, isn't a GLOBAL C-TAP better?

Wait. I thought that was the mantra of the 2017 Tax Cuts, so was that also Democrats? And aren’t interest rates 0 if borrowing is free? Really, what is the point of this Tweet?

via New York Times Opinion words worth reading nytimes.com/2020/10/13/opi…

So there are alternatives -- it make sense for developing countries to use existing capabilities, which a sharing platform like COVID-19 Technology Access Pool, to develop their own. Researchers Are Hatching a Low-Cost Coronavirus Vaccine nytimes.com/2021/04/05/hea…

FDA and large biopharma should work on helping smaller companies who lack all the resources needed for timely compliance -- remediation means there was delay, and delay hurts patients. endpts.com/new-study-show…

Aequus and reVision to Collaborate on Stargardt Disease Program prn.to/3iVXWZC

One would think with multiple vaccines to choose from, including 2 with mRNA tech and one apparently more durable than Pfizer/BioNTech, Biden could negotiate better contracts with Pfizer.

The Economic Mistake the Left Is Finally Confronting nytimes.com/2021/09/19/opi… Investors (governments, philanthropists, or impact investors) can shift production ("supply side") values from primarily profit-driven to outcome driven, with profit following. Pay for it if we mean it

So this is what “America First” means? Daily chart – America’s pandemic is now an outlier in the rich world economist.com/graphic-detail…

The U.S. patent system affects all Americans, so all Americans should have the ability to affect the patent system. Read our newest brief to learn why integrating more voices into the @USPTO's decisions will lead to a more equitable patent system.

Good ideas to increase public involvement in the patent system -- which make sense, since that system ultimately benefits the public

To celebrate #InternationalDayOfWomenAndGirlsInScience, we chatted with Dr. Valentina Dallacasagrande, reVision’s Co-Founder and Sr. Scientific Advisor, about her experience as a woman in science. Check out her comments here! linkedin.com/posts/revision…

KEI statement on license agreement between the NIH and the WHO Covid-19 Technology Access Pool (C-TAP): keionline.org/37782

October is #BlindnessAwarenessMonth to raise awareness about the blind and visually impaired community. Internationally, 2.2B people have a near or distant vision impairment. Learn more at our LinkedIn page. #DisabilityAwareness #EqualAccessibility #VisuallyImpaired #support

Today is #RareDiseaseDay, a globally-organized movement to raise awareness about #RareDiseases. At #reVision, we are focused on treating #StargardtDisease, a rare pediatric disease without a treatment or a cure. Learn more at our LinkedIn #CareAboutRare linkedin.com/posts/revision…

Learn about Dr. Patricia E. Bath, a trailblazer for women of color in ophthalmology on our LinkedIn page for #WomensHistoryMonth2023! #WomenLeaders #EmpowerWomen linkedin.com/posts/revision…

REMS are a condition for approval. Another condition for approval could be waiving injunctive relief for patents covering REMS -- and other patents that cover a product but do not qualify for Orange Book listing. A FRAM-like license is adequate value for REMS inventions.

An early start for reVision today! We are excited to be a part of the Stargardt's Connected Conference - engaged with the Stargardt's Connected community & learning about the latest research in #StargardtsDisease! #Stargardts2023 #StargardtsConnected #CareAboutRare